Literature DB >> 1502480

Cimetidine on-demand in dyspepsia. Experience with randomized controlled single-subject trials.

T Johannessen1, H Petersen, P Kristensen, D Fosstvedt, P M Kleveland, J Dybdahl, I Løge.   

Abstract

Double-blind randomized controlled trials in single subjects (N of 1 RCTs) have demonstrated a beneficial symptomatic effect of cimetidine in reflux- or ulcer-like non-ulcer dyspepsia (NUD). However, spontaneous fluctuations in symptoms reduce the validity of such trials when performed as continuous trials with fixed dosages. This study was carried out to identify individual responders to cimetidine in NUD, peptic ulcer disease, and oesophagitis and to confirm the beneficial average effect of cimetidine in these clinical entities. We evaluated N of 1 multi-crossover trial designs, which compare the effects of single doses of cimetidine and placebo taken on-demand for symptomatic relief. Each trial consisted of six cimetidine (400 mg or 800 mg) and six placebo tablets randomized in successive pairs. The symptomatic effect of each tablet was measured 1/2-6 h after the intake. Outcomes were assessed by individual p values and confidence intervals. A minimal clinically important difference was defined, to assess the clinical significance as demonstrated by the confidence intervals. Thirteen of 25 patients (52%) with reflux- and ulcer-like NUD obtained individual p values below 0.20. Similarly, 7 of 9 patients (78%) with oesophagitis and 6 of 12 patients (50%) with peptic ulcer obtained such p values. On the basis of the 80% confidence intervals the corresponding numbers of subjects with clinically significant effect were six (NUD), three, and three. The combined data showed a significantly better effect of cimetidine than of placebo (p less than 0.0001) in each of the three diagnostic groups studied. Cimetidine taken on-demand may have a rapid symptom-relieving effect in dyspepsia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1502480     DOI: 10.3109/00365529208999947

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  8 in total

1.  Individual (N-of-1) trials can be combined to give population comparative treatment effect estimates: methodologic considerations.

Authors:  Deborah R Zucker; Robin Ruthazer; Christopher H Schmid
Journal:  J Clin Epidemiol       Date:  2010-09-22       Impact factor: 6.437

2.  Long-term prescribing of proton pump inhibitors in general practice.

Authors:  A P Hungin; G P Rubin; H O'Flanagan
Journal:  Br J Gen Pract       Date:  1999-06       Impact factor: 5.386

Review 3.  H(2) receptor antagonists and prokinetics in dyspepsia: a critical review.

Authors:  Peter Bytzer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

4.  A randomized open-label trial of on-demand rabeprazole vs ranitidine for patients with non-erosive reflux disease.

Authors:  Abdallah A Kobeissy; Jana G Hashash; Faek R Jamali; Assaad M Skoury; Reham Haddad; Sarah El-Samad; Rami Ladki; Rola Aswad; Assaad M Soweid
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

Review 5.  Functional dyspepsia. Current treatment recommendations.

Authors:  Gerald Holtmann; Nicholas J Talley
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

6.  Randomised study of n of 1 trials versus standard practice.

Authors:  J Mahon; A Laupacis; A Donner; T Wood
Journal:  BMJ       Date:  1996-04-27

7.  Evaluation of person-level heterogeneity of treatment effects in published multiperson N-of-1 studies: systematic review and reanalysis.

Authors:  Gowri Raman; Ethan M Balk; Lana Lai; Jennifer Shi; Jeffrey Chan; Jennifer S Lutz; Robert W Dubois; Richard L Kravitz; David M Kent
Journal:  BMJ Open       Date:  2018-05-26       Impact factor: 2.692

8.  A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease.

Authors:  Fernando Sierra-Arango; D M Castaño; Jennifer D Forero; Erika D Pérez-Riveros; Gerardo Ardila Duarte; Maria L Botero; Andres Cárdenas; Jose De la Hoz-Valle
Journal:  Can J Gastroenterol Hepatol       Date:  2019-12-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.